A Phase I Open-label, Safety Study of Intra-tumoral Application of TMV-018 in Combination With 5-FC or Anti-PD-1 Therapy in Patients With Tumors of the Gastrointestinal Tract

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs TMV 018 (Primary) ; Antineoplastics; Flucytosine
Indications Carcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
Focus Adverse reactions; First in man
Sponsors Themis Bioscience

05 Dec 2020 Status changed from withdrawn prior to enrolment to discontinued.
23 Nov 2020 Planned End Date changed from 1 Dec 2023 to 23 Nov 2020.
23 Nov 2020 Planned primary completion date changed from 1 Dec 2021 to 23 Nov 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com